Skip to main content

Table 5 Odds ratios (OR) and corresponding 95% confidence intervals (CI) for TRG1 and tumor downstaging according to selected characteristics

From: Preoperative intensity-modulated radiotherapy with a simultaneous integrated boost combined with Capecitabine in locally advanced rectal cancer: short-term results of a multicentric study

 

TRG 1

OR (95% CI)a

Downstaging

OR (95% CI)a

 

n

(%)

n

(%)

Sex

 Man

13

(26.0)

Reference

34

(70.8)

Reference

 Woman

7

(26.9)

1.67 (0.60–4.62)

18

(72.0)

0.90 (0.21–3.88)

Age (years)

 < 55

5

(29.4)

Reference

12

(70.6)

Reference

 55–64

5

(18.5)

0.36 (0.10–1.27)

14

(56.0)

0.37 (0.07–1.99)

 65–74

6

(31.6)

1.01 (0.26–3.85)

16

(84.2)

2.93 (0.40–21.37)

 ≥ 75

4

(30.8)

0.85 (0.20–3.56)

10

(83.3)

2.75 (0.34–22.48)

Distance EAS (mm)

 < 60

9

(23.7)

Reference

29

(80.6)

Reference

 ≥ 60

8

(27.6)

0.88 (0.30–2.55)

17

(58.6)

0.12 (0.02–0.69)

 Unknown

3

(33.3)

1.026 (0.22–7.12)

6

(75.0)

0.15 (0.01–2.43)

cT

 cT2

2

(40.0)

Reference

3

(100.0)

-

 cT3

17

(27.0)

0.29 (0.02–4.14)

42

(67.7)

-

 cT4

1

(12.5)

0.29 (0.02–5.68)

7

(87.5)

-

cN

 cN0

4

(33.3)

Reference

8

(66.7)

Reference

 cN1

10

(25.6)

0.59 (0.16–2.23)

25

(67.6)

0.39 (0.06–2.60)

 cN2

6

(24.0)

0.77 (0.18–3.34)

19

(79.2)

1.14 (0.17–7.82)

MRF involvment

 No

6

(17.7)

Reference

31

(79.5)

Reference

 Yes

14

(33.3)

0.34 (0.11–1.01)

21

(61.8)

0.29 (0.07–1.18)

Single dose intensity

 2.1

3

(18.8)

Reference

12

(80.0)

Reference

 2.16

9

(37.5)

1.45 (0.36–5.84)

15

(62.5)

0.16 (0.02–1.47)

 ≥ 2.2

8

(22.2)

1.45 (0.39–5.38)

25

(73.5)

1.14 (0.14–9.25)

  1. aAdjusted for all variables reported in the table